Amphotericin b lipid complex Disease Interactions

Amphotericin B lipid complex may depress red blood cell production and occasionally causes a normocytic, normochromic anemia. A 4% incidence was reported during clinical trials. Although the anemia is generally well tolerated and reverses completely after discontinuation of therapy, it may be problematic in patients with preexisting anemia. Therapy with amphotericin B lipid complex should be administered cautiously in anemic patients. Frequent blood counts and hematocrit levels are recommended.

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause hypo- and hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment. Renal function and serum electrolytes should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting electrolyte abnormalities. Mineral and electrolyte supplementation may likely be required. Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.

Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause decreased renal function and abnormalities such as hypo- and hyperkalemia, hypomagnesemia, and renal tubular acidosis. Renal function should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting renal impairment. Serum creatinine, BUN, potassium and magnesium levels should be evaluated regularly, and dosing adjusted or discontinued if necessary. Hydration with normal saline may decrease the risk for nephrotoxicity. In addition, administration of alkali medication may help to prevent renal tubular acidosis.